TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Co-Infection
Research from D. Laureillard and co-authors in the area of HIV/AIDS co-infection published
September 23rd, 2008
According to recent research published in the journal HIV Medicine, " Efavirenz is used for the antiretroviral treatment of HIV/tuberculosis-coinfected patients in developing countries. A switch to nevirapine is regularly carried out because of the cost and side effects of efavirenz." "Pharmacokinetic studies suggested that nevirapine should be initiated at full dose when used as a substitute for efavirenz. Objectives The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN). In 2001 an antiretroviral treatment programme was initiated...
Source: TB & Outbreaks Week (2008-09-23)
|
